{"nctId":"NCT00532935","briefTitle":"MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)","startDateStruct":{"date":"2008-01-26","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":517,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: sitagliptin phosphate (+) metformin hydrochloride"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: pioglitazone"]}],"interventions":[{"name":"sitagliptin phosphate (+) metformin hydrochloride","otherNames":["Janumet"]},{"name":"Comparator: pioglitazone","otherNames":["pioglitazone"]}],"eligibilityModule":{"eligibilityCriteria":"General Inclusion Criteria:\n\n* Patient has type 2 diabetes mellitus\n* Patient is inadequately controlled and not on treatment with insulin or oral antihyperglycemic therapy\n\nGeneral Exclusion Criteria:\n\n* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis\n* Patient was on antihyperglycemic agent therapy (oral or insulin) within the prior 12 weeks\n* Patient was on \\>4 weeks (cumulatively) of antihyperglycemic therapy (oral or insulin) over the prior 3 years","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in A1C at Week 32","description":"A1C is measured as a percent. Thus this change from baseline reflects the Week 32 A1C percent minus the baseline A1C percent","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.86","spread":null},{"groupId":"OG001","value":"-1.39","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 1","description":"Change from baseline reflects the Week 1 FPG minus the baseline FPG. At Week 1, the dose was 50/500 mg b.i.d. for Sita/Met FDC and 30 mg q.d. for pioglitazone","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.5","spread":null},{"groupId":"OG001","value":"-13.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour Post-Meal Glucose (PMG) at Week 32","description":"Change from baseline reflects the Week 32 2-hour PMG minus the baseline 2-hour PMG","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-102.2","spread":null},{"groupId":"OG001","value":"-82.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG at Week 32","description":"Change from baseline reflects the Week 32 FPG minus the baseline FPG","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-56.0","spread":null},{"groupId":"OG001","value":"-44.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With A1C <7.0% at Week 32","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":null},{"groupId":"OG001","value":"43.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":261},"commonTop":["Diarrhoea","Hypoglycaemia","Upper respiratory tract infection","Headache","Nasopharyngitis"]}}}